Modulators of rituximab-induced complement-dependent cytotoxicity in diffuse large B-cell lymphoma

Rituximab, the chimeric monoclonal antibody targeting CD20, forms the cornerstone of therapy for diffuse large B-cell lymphoma (DLBCL). However, more than one-third of patients eventually become unresponsive or resistant to rituximab. Although the mechanisms of action and resistance are not well und...

ver descrição completa

Detalhes bibliográficos
Autor principal: Ong, Charmaine Zi Yan
Outros Autores: -
Formato: Final Year Project (FYP)
Idioma:English
Publicado em: Nanyang Technological University 2021
Assuntos:
Acesso em linha:https://hdl.handle.net/10356/149717